13075_2021_2709_MOESM3_ESM.pptx (68.43 kB)
Additional file 3 of Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models
presentation
posted on 2022-01-06, 04:29 authored by Cindy Orvain, Anne Cauvet, Alexis Prudent, Christophe Guignabert, Raphaël Thuillet, Mina Ottaviani, Ly Tu, Fanny Duhalde, Carole Nicco, Frédéric Batteux, Jérôme Avouac, NingXin Wang, Michelle A. Seaberg, Stacey R. Dillon, Yannick AllanoreAdditional file 3: Supplementary Figure 2. Experimental design of acazicolcept (ALPN-101) treatment in Fra-2 Tg mice model. Twelve-week-old female Fra-2 transgenic mice were divided into two groups treated with: Fc control (n=8) and acazicolcept (n=11). Fc control or acazicolcept were injected intraperitoneally twice a week for six weeks. After six weeks of treatment, mice were euthanized, and lungs and spleen were collected for analysis.
